SINGH, A., Mohammad Salman HUSSAIN, V. KHER, A. J. PALMER, M. JOSE and B. ANTONY. A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. ABINGDON: TAYLOR & FRANCIS LTD, 2022, vol. 22, No 1, p. 27-35. ISSN 1473-7167. Available from: https://dx.doi.org/10.1080/14737167.2021.1916471.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury
Authors SINGH, A., Mohammad Salman HUSSAIN (356 India, belonging to the institution), V. KHER, A. J. PALMER, M. JOSE and B. ANTONY (guarantor).
Edition EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, ABINGDON, TAYLOR & FRANCIS LTD, 2022, 1473-7167.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.300
RIV identification code RIV/00216224:14110/22:00124962
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1080/14737167.2021.1916471
UT WoS 000646164100001
Keywords in English Acute kidney injury; cost-effectiveness analysis; CRRT; dialysis; health economics; IRRT; systematic review
Tags 14119612, 14119613, rivok
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 1/2/2022 10:19.
Abstract
Introduction Though cost-effectiveness analyses (CEAs) have evaluated continuous renal replacement therapy (RRTs) and intermittent RRTs in acute kidney injury (AKI) patients; it is yet to establish which RRT technique is most cost-effective. We systematically reviewed the current evidence from CEAs of CRRT versus IRRT in patients with AKI. Areas covered PubMed, EMBASE, and Cochrane databases searched for CEAs comparing two RRTs. Overall, seven CEAs, two from Brazil and one from US, Canada, Colombia, Belgium, and Argentina were included. Five CEAs used Markov model, three reported following CHEERS, none accounted indirect costs. Time horizon varied from 1-year-lifetime. Marginal QALY gain with CRRT compared to IRRT was reported across CEAs. Older CEAs found CRRT to be costlier and not cost-effective than IRRT (ICER 2019 US$: 152,671$/QALY); latest CEAs (industry-sponsored) reported CRRT to be cost-saving versus IRRT (-117,614$/QALY). Risk of mortality, dialysis dependence, and incidence of renal recovery were the key drivers of cost-effectiveness. Expert opinion CEAs of RRTs for AKI show conflicting findings with secular trends. Latest CEAs suggested CRRT to be cost-effective versus IRRT with dialysis dependence rate as major driver of cost-effectiveness. Future CEAs, preferably non-industry sponsored, may account for indirect costs to improve the generalizability of CEAs.
PrintDisplayed: 28/5/2024 06:11